The Cooper Companies, Inc. (NASDAQ:COO) Shares Sold by Kintegral Advisory LLC

Kintegral Advisory LLC lowered its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 4.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,810 shares of the medical device company’s stock after selling 550 shares during the period. Kintegral Advisory LLC’s holdings in Cooper Companies were worth $1,086,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Victory Capital Management Inc. raised its holdings in Cooper Companies by 23.0% in the third quarter. Victory Capital Management Inc. now owns 3,950,119 shares of the medical device company’s stock valued at $435,856,000 after acquiring an additional 737,726 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Cooper Companies by 13.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 4,930,022 shares of the medical device company’s stock valued at $543,979,000 after purchasing an additional 573,908 shares in the last quarter. International Assets Investment Management LLC purchased a new stake in shares of Cooper Companies during the 3rd quarter worth $46,727,000. Swedbank AB grew its stake in shares of Cooper Companies by 14.0% during the fourth quarter. Swedbank AB now owns 1,629,602 shares of the medical device company’s stock worth $149,809,000 after purchasing an additional 200,000 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Cooper Companies by 11.9% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,818,610 shares of the medical device company’s stock valued at $200,665,000 after buying an additional 194,118 shares during the last quarter. Hedge funds and other institutional investors own 24.39% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on COO. Citigroup decreased their price target on Cooper Companies from $116.00 to $115.00 and set a “buy” rating for the company in a report on Friday, December 6th. Wells Fargo & Company boosted their target price on Cooper Companies from $115.00 to $118.00 and gave the stock an “overweight” rating in a research note on Friday, December 6th. Needham & Company LLC reiterated a “hold” rating on shares of Cooper Companies in a research note on Friday, December 6th. Morgan Stanley cut their price objective on shares of Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a report on Friday, December 6th. Finally, StockNews.com cut shares of Cooper Companies from a “buy” rating to a “hold” rating in a report on Wednesday, December 11th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $117.00.

Cooper Companies Stock Performance

NASDAQ COO opened at $88.48 on Friday. The firm has a market cap of $17.66 billion, a P/E ratio of 45.37, a P/E/G ratio of 2.25 and a beta of 1.00. The Cooper Companies, Inc. has a 52-week low of $84.76 and a 52-week high of $112.38. The business’s 50-day moving average price is $92.94 and its 200 day moving average price is $99.60. The company has a quick ratio of 1.12, a current ratio of 1.91 and a debt-to-equity ratio of 0.32.

Cooper Companies (NASDAQ:COO) last announced its earnings results on Thursday, December 5th. The medical device company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.04. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.03 billion. During the same period last year, the business posted $0.87 EPS. The company’s revenue was up 9.8% on a year-over-year basis. On average, equities research analysts expect that The Cooper Companies, Inc. will post 3.98 earnings per share for the current year.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.